Swiss Re AG (OTCMKTS:SSREY – Get Free Report) was the target of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 3,400 shares, a decrease of 71.9% from the October 31st total of 12,100 shares. Based on an average daily volume of 55,700 shares, the days-to-cover ratio is currently 0.1 days.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on the company. UBS Group upgraded Swiss Re from a “strong sell” rating to a “strong-buy” rating in a research report on Monday, November 11th. The Goldman Sachs Group upgraded shares of Swiss Re to a “strong sell” rating in a report on Wednesday, September 18th. Citigroup upgraded shares of Swiss Re to a “strong-buy” rating in a report on Monday, November 18th. Keefe, Bruyette & Woods upgraded shares of Swiss Re from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Finally, Berenberg Bank upgraded Swiss Re to a “strong-buy” rating in a report on Monday, November 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy”.
Read Our Latest Stock Analysis on Swiss Re
Swiss Re Stock Performance
Swiss Re Company Profile
Swiss Re AG, together with its subsidiaries, provides wholesale reinsurance, insurance, other insurance-based forms of risk transfer, and other insurance-related services worldwide. The company operates through three segments: Property & Casualty Reinsurance, Life & Health Reinsurance, and Corporate Solutions.
Featured Stories
- Five stocks we like better than Swiss Re
- Consumer Staples Stocks, Explained
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- What is the Nikkei 225 index?
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Investing in Commodities: What Are They? How to Invest in Them
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Swiss Re Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swiss Re and related companies with MarketBeat.com's FREE daily email newsletter.